Non-Cancerous Blood Disease Market Segmentation:
Disease Type Segment Analysis
Under the disease type segment, anemia iron deficiency dominates the segment and is expected to hold the market share of 28.7% by 2034. Iron-deficiency anemia is the most common non-cancerous blood disorder worldwide. It is estimated by the World Health Organization that more than 1.5 billion women and children have iron deficiency, with significant effects in low-income and developed nations alike. Rising rates of diagnosis, national programs for supplementation, and diet intervention have led to demand for oral and intravenous iron treatments. For example, the U.S. CDC's Iron and Micronutrient Initiative aids iron fortification in public nutrition, driving treatment coverage.
Treatment Type Segment Analysis
In the treatment type segment, erythropoiesis-stimulating agents (ESAs) are leading the market and are projected to hold a market share of 25.9% by 2034. Erythropoiesis-stimulating agents are the therapy for chronic anemia, mainly in patients having kidney disease and undergoing chemotherapy. As per the Medicare report, ESAs are reimbursed under ESRD bundles and Part B drug coverage, supporting widespread adoption in both outpatient and inpatient settings. Further, NIH-funded research on biosimilar ESA safety has up surged the competition and pricing stability. This research has made an improvement in both developed and developing countries.
Our in-depth analysis of the global non-cancerous blood disease market includes the following segments:
|
Segment |
Subsegment |
|
Disease Type |
|
|
Treatment Type |
|
|
End user |
|
